- Home
- PROK vs ETON Comparison
PROK vs ETON Comparison
Compare PROK & ETON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PROK
- ETON
- Stock Information
- Founded
- PROK 2015
- ETON 2017
- Country
- PROK United States
- ETON United States
- Employees
- PROK N/A
- ETON N/A
- Industry
- PROK Biotechnology: Biological Products (No Diagnostic Substances)
- ETON Biotechnology: Pharmaceutical Preparations
- Sector
- PROK Health Care
- ETON Health Care
- Exchange
- PROK Nasdaq
- ETON Nasdaq
- Market Cap
- PROK 334.8M
- ETON 388.3M
- IPO Year
- PROK N/A
- ETON 2018
- Fundamental
- Price
- PROK $2.45
- ETON $17.78
- Analyst Decision
- PROK Buy
- ETON Strong Buy
- Analyst Count
- PROK 5
- ETON 3
- Target Price
- PROK $6.25
- ETON $29.67
- AVG Volume (30 Days)
- PROK 2.4M
- ETON 220.9K
- Earning Date
- PROK 11-11-2025
- ETON 11-11-2025
- Dividend Yield
- PROK N/A
- ETON N/A
- EPS Growth
- PROK N/A
- ETON N/A
- EPS
- PROK N/A
- ETON N/A
- Revenue
- PROK $527,000.00
- ETON $58,181,000.00
- Revenue This Year
- PROK $265.05
- ETON $105.25
- Revenue Next Year
- PROK N/A
- ETON $40.84
- P/E Ratio
- PROK N/A
- ETON N/A
- Revenue Growth
- PROK N/A
- ETON 85.40
- 52 Week Low
- PROK $0.46
- ETON $5.18
- 52 Week High
- PROK $7.13
- ETON $21.48
- Technical
- Relative Strength Index (RSI)
- PROK 50.33
- ETON 61.57
- Support Level
- PROK $2.12
- ETON $17.22
- Resistance Level
- PROK $3.05
- ETON $18.06
- Average True Range (ATR)
- PROK 0.23
- ETON 0.67
- MACD
- PROK 0.03
- ETON -0.05
- Stochastic Oscillator
- PROK 35.48
- ETON 59.65
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's cells isolated from the patient intended for treatment. Its product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.
About ETON Eton Pharmaceuticals Inc.
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector.